MedTrace Logo

SXC-2023 Cocaine Interaction Study

NCT06343532 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-24

Study results available
· View outcomes & findings →

Summary

The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.

Conditions

  • Cocaine Use Disorder

Interventions

DRUG

SXC-2023

200 mg capsules

DRUG

SXC-2023 Placebo

200 mg capsules

Sponsors & Collaborators

  • Promentis Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Altasciences Company Inc.

    collaborator INDUSTRY

  • Technical Resources International, Inc.

    collaborator UNKNOWN

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Debra Kelsh, MD · Altasciences Clinical Kansas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2024-12-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06343532 on ClinicalTrials.gov